Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke (MIRACLE)

November 25, 2025 updated by: Wan-Jin Chen

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Strokes With Large Infarct: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial (MIRACLE)

The efficacy and safety of methylprednisolone in acute ischemic stroke patients with large infarct cores (ASPECTS score < 6 or infarct volume ≥50 mL) due to anterior circulation large vessel occlusion have not been clearly established. This is a multi-center, randomized, double-blind, placebo-controlled trial to investigate early combination therapy with methylprednisolone for reperfusion in acute large core infarction.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
928

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • China
    • Anhui
      • Hefei, Anhui, China, 230001
        • The First Affiliated hospital of USTC
      • Hefei, Anhui, China, 230061
        • Hefei First People's Hospital
      • Taihe Chengguanzhen, Anhui, China, 236600
        • Taihe County People's Hospital
      • Wuhu, Anhui, China, 241001
        • Yijishan Hospital of Wannan Medical College
    • Fujian
      • Anxi, Fujian, China, 362400
        • Anxi County Hospital
      • Anxi, Fujian, China, 362400
        • Anxi Hospital of Traditional Chinese Medicine
      • Fuqing, Fujian, China, 350300
        • Fuqing City Hospital of Fujian
      • Fuzhou, Fujian, China, 350001
        • Union Hospital Affiliated to Fujian Medical University
      • Fuzhou, Fujian, China, 350001
        • Fuzhou University Affiliated Provincial Hospital
      • Fuzhou, Fujian, China, 350003
        • The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine
      • Fuzhou, Fujian, China, 350005
        • Department of Neurology, First Affiliated Hospital Fujian Medical University
      • Fuzhou, Fujian, China, 350025
        • 900th Hospital of PLA Joint Logistic Support Force
      • Longyan, Fujian, China, 364000
        • Longyan First Affiliated Hospital of Fujian Medical University
      • Nanping, Fujian, China, 353000
        • Nanping First Hospital
      • Ningde, Fujian, China, 352100
        • Ningde Municipal Hospital, Ningde Normal University
      • Ningde, Fujian, China, 352100
        • Mindong Hospital
      • Putian, Fujian, China, 351100
        • The First Hospital of Putian City
      • Putian, Fujian, China, 351100
        • Putian University Affiliated Hospital
      • Quanzhou, Fujian, China, 362000
        • The Second Affiliated Hospital of Fujian Medical University
      • Quanzhou, Fujian, China, 362000
        • Quanzhou First Hospital Affiliated to Fujian Medical University
      • Quanzhou, Fujian, China, 362000
        • The 910th Hospital of the Joint Logistics Support Force of the Chinese PLA
      • Sanming, Fujian, China, 365000
        • Sanming First Hospital
      • Shaowu, Fujian, China, 354000
        • Shaowu Municiple Hospital
      • Xiamen, Fujian, China, 361003
        • The first affiliated hospital of xiamen university
      • Xiamen, Fujian, China, 361004
        • Zhongshan Hosipital Xiamen University
      • Zhangzhou, Fujian, China, 363000
        • Zhangzhou Municipal Hospital of Fujian Province
      • Zhangzhou, Fujian, China, 363000
        • 909th Hospital of PLA Joint Logistic Support Force
    • Gansu
      • Lanzhou, Gansu, China, 730050
        • Gansu Province Central Hospital
    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
      • Maoming, Guangdong, China, 525000
        • Maoming People's Hospital
      • Maoming, Guangdong, China, 525000
        • Maoming Hospital of Traditional Chinese Medicine
      • Shantou, Guangdong, China, 515031
        • Shantou Central Hospital
      • Zhanjiang, Guangdong, China, 524001
        • Affiliated Hospital Of Guangdong Medical University
      • Zhanjiang, Guangdong, China, 524037
        • Central people' s hospital of zhanjiang
    • Guangxi
      • Yulin, Guangxi, China, 537000
        • Red Cross Hospital of Yulin City
    • Guangzhou
      • Guangzhou, Guangzhou, China, 510180
        • Guangzhou First People's Hospital
    • Guizhou
      • Qingzhen, Guizhou, China, 551400
        • The First People's Hospital of Qingzhen
    • Hainan
      • Haikou, Hainan, China, 570102
        • The First Affiliated Hospital of Hainan Medical University
      • Haikou, Hainan, China, 570311
        • The Second Affiliated Hospital of Hainan Medical University
    • Henan
      • Bishui, Henan, China, 463700
        • Biyan People's Hospital
      • Wacheng Neighborhood, Henan, China, 466600
        • Xihua People's Hospital
      • Zhoukou, Henan, China, 466000
        • Zhoukou Centeral Hospital
      • Zhumadian, Henan, China, 463000
        • ZhuMaDian Centeral Hospital
      • Zhumadian, Henan, China, 463000
        • Zhumadian First People's Hospital
    • Hubei
      • Enshi, Hubei, China, 445000
        • The Central Hospital of Enshi Tujia And Miao Automomous Prefecture
      • Ezhou, Hubei, China, 436000
        • Ezhou Central Hospital
      • Huanggang, Hubei, China, 435300
        • Qichun People's Hospital
      • Huanggang, Hubei, China, 438000
        • Huanggang Central Hospital
      • Huangshi, Hubei, China, 435000
        • Huangshi Central Hospital
      • Jingzhou, Hubei, China, 434000
        • Yangtze University Affiliated Hospital
      • Jingzhou, Hubei, China, 434020
        • Jingzhou Hospital Affiliated to Yangtze University
      • Lichuan, Hubei, China, 445400
        • Lichuan City Ethnic Traditional Chinese Medical Hospital
      • Shiyan, Hubei, China, 442000
        • Shiyan Renmin Hospital
      • Shiyan, Hubei, China, 442000
        • Shiyan Hospital of Integrated Traditional and Western Medicine
      • Shiyan, Hubei, China, 442000
        • Taihe Hospital Affiliated to Hubei University of Medicine
      • Tianmen, Hubei, China, 431700
        • The First People's Hospital of Tianmen in Hubei Province
      • Wuhan, Hubei, China, 430071
        • Zhongnan Hospital of Wuhan University
      • Wuhan, Hubei, China, 430030
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, Hubei, China, 430022
        • Wuhan No.1 Hospital
      • Wuhan, Hubei, China, 430012
        • Wuhan Hankou Hospital
      • Wuhan, Hubei, China, 430014
        • The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, Hubei, China, 430033
        • The Third People's Hospital of Hubei Province
      • Wuhan, Hubei, China, 430060
        • Wuhan University Renmin Hospital
      • Wuhan, Hubei, China, 430200
        • The First people's Hospital of Jiangxia District
      • Xiangyang, Hubei, China, 441000
        • Xiangyang Hospital of Traditional Chinese Medicine
      • Xiangyang, Hubei, China, 441000
        • Xiangyang No.1 People's Hospital, Hubei University of Medicine.
      • Xianning, Hubei, China, 437100
        • Xianning Central Hospital
      • Yichang, Hubei, China, 443000
        • The Second People's Hospital of Yichang
    • Inner Mongolia
      • Baotou, Inner Mongolia, China, 14040
        • Baotou Central Hospital
    • Jiangsu
      • Xuzhou, Jiangsu, China, 221002
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Ganzhou, Jiangxi, China, 341000
        • First Affiliated Hospital of Gannan Medical University
      • Ganzhou, Jiangxi, China, 341000
        • Ganzhou People's Hospital, Ganzhou (G.Z.)
      • Jingdezhen, Jiangxi, China, 333000
        • Jingdezhen First People's Hospital
      • Jiujiang, Jiangxi, China, 332000
        • Jiujiang University Affiliated Hospital
      • Jiujiang, Jiangxi, China, 332000
        • The First People's Hospital of Jiujiang
      • Nanchang, Jiangxi, China, 330006
        • Jiangxi Provincial People's Hospital
      • Nanchang, Jiangxi, China, 330006
        • The First Affiliated Hospital, Jiangxi Medical College, Nanchang University
      • Yingtan, Jiangxi, China, 335000
        • Yingtan People's Hospital
    • Shaanxi
      • Xianyang, Shaanxi, China, 712000
        • The First People's Hospital of Xianyang
    • Shandong
      • Jinan, Shandong, China, 250011
        • Affiliated Hospital of Shandong University of Traditional Chinese Medicine
      • Jinan, Shandong, China, 250013
        • Jinan Central Hospital Affiliated to Shandong First Medical University
      • Liaocheng, Shandong, China, 252000
        • Liaocheng People's Hospital
      • Liaocheng, Shandong, China, 252000
        • Liaocheng Third People's Hospital
      • Qingdao, Shandong, China, 266003
        • The Affiliated Hospital of Qingdao Univercity
      • Tai’an, Shandong, China, 271000
        • The Second Affiliated Hospital of Shandong First Medical University
      • Zoucheng, Shandong, China, 273500
        • Zoucheng People's Hospital, Shandong Province
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200025
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    • Shanxi
      • Taiyuan, Shanxi, China, 30012
        • Shanxi Provincial People's Hospital
      • Taiyuan, Shanxi, China, 30001
        • Cardiovascular Hospital Affiliated to Shanxi Medical University
    • Sichuan
      • Chengdu, Sichuan, China, 611230
        • Chongzhou People's Hospital
      • Gulin, Sichuan, China, 646500
        • Gulin County People's Hospital
      • Mianyang, Sichuan, China, 621000
        • Mianyang 404 Hospital
      • Mianyang, Sichuan, China, 621000
        • Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China
      • Nanchong, Sichuan, China, 637000
        • Affiliated Hospital of North Sichuan Medical College
      • Suining, Sichuan, China, 629000
        • Suining Central Hospital
      • Zigong, Sichuan, China, 643020
        • Zigong Third People's Hospital
    • Tian
      • Tianjin, Tian, China, 300350
        • Tianjin Huanhu Hospital
    • Xinjiang
      • Bole, Xinjiang, China, 833400
        • Bozhou People's Hospital
    • Yunnan
      • Qujing, Yunnan, China, 655000
        • Qujing NO.1 Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 18 years.
  • The time from onset to randomization was within 12 hours.
  • Anterior circulation ischemic stroke was preliminarily determined according to clinical symptoms or imaging examination.
  • Occlusion of the intracranial internal carotid artery, the M1- or M2-segment of the middle cerebral artery by confirmed by CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA).
  • Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6.
  • Baseline Alberta Stroke Program Early CT Score (ASPECTS) < 6 (based on non-contrast CT or MRI) and/or core infarct volume ≥ 50 ml (based on CTP with rCBF < 30%).
  • Planned treatment with endovascular thrombectomy (EVT).
  • Informed consent obtained from patients or their legal representatives.

Exclusion Criteria:

  • Intracranial hemorrhage confirmed by cranial CT or MRI.
  • mRS score > 2 before onset.
  • Pregnant or lactating women.
  • Allergic to contrast agents or glucocorticoids.
  • Participating in other clinical trials.
  • The artery is tortuous so that the thrombectomy device cannot reach the target vessel.
  • Bleeding history (gastrointestinal and urinary tract bleeding) in recent 1 month.
  • Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate < 30 ml/min or serum creatinine > 220 umol/L [2.5 mg/ dL]).
  • Life expectancy due to any advanced disease < 6 months.
  • Follow-up is not expected to be completed.
  • Intracranial aneurysm and arteriovenous malformation.
  • Brain tumors with imaging mass effect.
  • Systemic infectious disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Methylprednisolone sodium succinate group
Drug: Methylprednisolone sodium succinate
Intravenous injection of methylprednisolone sodium succinate (Chongqing Lai Mei Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomisation. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
Placebo Comparator: Placebo group
Methylprednisolone sodium succinate simulant
Drug: Placebo
Intravenous injection of placebo (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
All-cause mortality at 90 (±14) days
Time Frame: From randomization to 90 (±14) days
Primary Efficacy Outcome. Defined as the number of any cause deaths observed divided by the number of subjects observed over the 90-day study period.
From randomization to 90 (±14) days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Incidence of any complications
Time Frame: From date of randomization until the date of discharge, an average of 1 week
Secondary Safety Outcome
From date of randomization until the date of discharge, an average of 1 week
Time from randomization to the occurrence of death from any cause at 90 (±14) days
Time Frame: From randomization to 90 (±14) days
Secondary Efficacy Outcome; To evaluate death rate of the two treatment groups
From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 4 at 90 (±14) days
Time Frame: From randomization to 90 (±14) days
Secondary Efficacy Outcome
From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 3 at 90 (±14) days
Time Frame: From randomization to 90 (±14) days
Secondary Efficacy Outcome
From randomization to 90 (±14) days
Proportion of patients with decompressive craniectomy after EVT
Time Frame: From randomization until the date of discharge, an average of 1 week
Secondary Efficacy Outcome
From randomization until the date of discharge, an average of 1 week
NIHSS score at 5-7 days or at early discharge
Time Frame: From randomization to 5-7 days ( or at early discharge)
Secondary Efficacy Outcome
From randomization to 5-7 days ( or at early discharge)
EQ-5D-5L VAS at 90 (±14) days
Time Frame: From randomization to 90 (±14) days
Secondary Efficacy Outcome
From randomization to 90 (±14) days
Proportion of patients with symptomatic intracranial haemorrhage (SICH) within 48 hours after EVT
Time Frame: From randomization to 48 hours
Primary Safety Outcome. Based on the modified Heidelberg Bleeding Classification.
From randomization to 48 hours
Proportion of patients with any intracranial haemorrhage (ICH) within 48 hours after EVT
Time Frame: From randomization to 48 hours
Secondary Safety Outcome. Based on the modified Heidelberg Bleeding Classification.
From randomization to 48 hours
Proportion of patients with pneumonia
Time Frame: From randomization until the date of discharge, an average of 1 week
Secondary Safety Outcome
From randomization until the date of discharge, an average of 1 week
Proportion of patients with gastrointestinal haemorrhage within 7 days after EVT
Time Frame: From randomization to 7 days
Secondary Safety Outcome
From randomization to 7 days
Incidence of any (serious) adverse events
Time Frame: From randomization to 90 (±14) days
Secondary Safety Outcome
From randomization to 90 (±14) days
Midline shift at 48 hours
Time Frame: From randomization to 48 hours
Secondary Efficacy Outcome
From randomization to 48 hours
Net water uptake at 48 hours
Time Frame: From randomization to 48 hours
Secondary Efficacy Outcome
From randomization to 48 hours
mRS ordinal shift at 90 (±14) days (scores 5 and 6 are merged)
Time Frame: From randomization to 90 (±14) days
Secondary Efficacy Outcome
From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 2 at 90 (±14) days
Time Frame: From randomization to 90 (±14) days
Secondary Efficacy Outcome
From randomization to 90 (±14) days
Proportion of patients with mRS score 0 to 1 at 90 (±14) days or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)
Time Frame: From randomization to 90 (±14) days
Secondary Efficacy Outcome
From randomization to 90 (±14) days
Proportion of patients with midline shift >5 mm within 48 hours after EVT
Time Frame: From randomization to 48 hours
Secondary Efficacy Outcome
From randomization to 48 hours
Relative hemispheric volume at 48 hours
Time Frame: From randomization to 48 hours
Secondary Efficacy Outcome.
From randomization to 48 hours

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
EQ-5D-5L VAS at 1 year
Time Frame: From randomization to 1 year
Tertiary Efficacy Outcome
From randomization to 1 year
EQ-5D-5L VAS at 5 years
Time Frame: From randomization to 5 years
Tertiary Efficacy Outcome
From randomization to 5 years
mRS ordinal shift at 1 year (scores 5 and 6 are merged)
Time Frame: From randomization to 1 year
Tertiary Efficacy Outcome
From randomization to 1 year
Proportion of patients with mRS score 0 to 2 at 1 year
Time Frame: From randomization to 1 year
Tertiary Efficacy Outcome
From randomization to 1 year
Proportion of patients with mRS score 0 to 1 at 1 year or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)
Time Frame: From randomization to 1 year
Tertiary Efficacy Outcome
From randomization to 1 year
mRS ordinal shift at 5 years (scores 5 and 6 are merged)
Time Frame: From randomization to 5 years
Tertiary Efficacy Outcome
From randomization to 5 years
Proportion of patients with mRS score 0 to 2 at 5 years
Time Frame: From randomization to 5 years
Tertiary Efficacy Outcome
From randomization to 5 years
Proportion of patients with mRS score 0 to 1 at 5 years or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)
Time Frame: From randomization to 5 years
Tertiary Efficacy Outcome
From randomization to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Wan-Jin Chen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 30, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2030

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 7, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 7, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 11, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 3, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 25, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MRCTA,ECFAH of FMU[2024]368-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Ischemic Stroke

Clinical Trials on Methylprednisolone sodium succinate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings